Urologic Oncology: Seminars and Original Investigations
Volume 29, Issue 6 , Pages 676-681 , November 2011

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer

  • Stephanie Jeske, M.D.

      Affiliations

    • Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10065, USA
    • ,
  • Scott T. Tagawa, M.D.

      Affiliations

    • Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10065, USA
    • ,
  • Olugbenga Olowokure, M.D.

      Affiliations

    • Division of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    • ,
  • Jodi Selzer, F.N.P.

      Affiliations

    • Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10065, USA
    • ,
  • Paraskevi Giannakakou, Ph.D.

      Affiliations

    • Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10065, USA
    • ,
  • David M. Nanus, M.D.

      Affiliations

    • Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10065, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-212-746-3152; fax: +1-212-746-6645

Received 3 September 2009 ,Revised 30 December 2009 ,Accepted 31 December 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Tannock I, Osoba D, Stockler M, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764
  3. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999;17:2506–2513
  4. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520
  5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512
  6. Canobbio L, Guarneri D, Miglietta L, et al. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer. 1993;29A:2094–2096
  7. Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. J Clin Oncol. 2007;25:5019;(Meeting Abstracts)
  8. Nakabayashi M, Sartor O, Jacobus S, et al. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU International. 2008;101:308–312
  9. Flaig TW, Barqawi A, Miller G, et al. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer. 2006;107:266–274
  10. Cabrespine A, Guy L, Khenifar E, et al. Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Urology. 2006;67:354–359
  11. Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001;19:44–53
  12. Berry W, Friedland D, Fleagle J, et al. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer. 2006;5:131–137
  13. Oh WK, Hagmann E, Manola J, et al. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005;11:284–289
  14. Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma. Cancer. 2003;98:2592–2598
  15. Ross RW, Beer TM, Jacobus S, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112:521–526
  16. Solit DB, Morris M, Slovin S, et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer. 2003;98:1842–1848
  17. Urakami S, Igawa M, Kikuno N, et al. Combination chemotherapy with paclitaxel, estramustine, and carboplatin for hormone refractory prostate cancer. J Urol. 2002;168:2444–2450
  18. Mathew P, DiPaola R. Taxane refractory prostate cancer. J Urol. 2007;178:S36–S41
  19. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials working group. J Clin Oncol. 2008;26:1148–1159
  20. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients. Cancer. 2007;110:556–563
  21. Loriot Y, Massard C, Gross-Goupil M, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: A prospective study evaluating also neuroendocrine features. Ann Oncol. 2009;20:703–708
  22. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–481
  23. Sternberg C, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology. 2005;68:2–9
  24. Valero V, Jones S, Von Hoff D, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998;16:3362–3368
  25. Taguchi T, Aihara T, Takatsuka Y, et al. Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan. Breast J. 2004;10:509–513
  26. Seidman A, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol. 1996;14:1877–1884
  27. Giannakakou P, Sackett DL, Kang Y-K, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997;272:17118–17125
  28. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. PNAS. 2000;97:2904–2909
  29. Giannakakou P, Snyder JP. Resistance to Microtubule-Targeting Drugs. In:  Fojo AT editors. Cancer drug discovery and development: Microtubule targets in cancer therapy. Totowa, NJ: Humana Press Inc.; 2008;p. 357–394
  30. Snyder JP, Nettles JH, Cornett B, et al. The binding conformation of taxol in β-tubulin: A model based on electron crystallographic density. Proc Natl Acad Sci U S A. 2001;98:5312–5316
  31. Thall PF, Logothetis C, Pagliaro LC, et al. Adaptive therapy for androgen-independent prostate cancer: A randomized selection trial of four regimens. J Natl Cancer Inst. 2007;99:1613–1622
  32. Machiels J-P, Mazzeo F, Clausse M, et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.. J Clin Oncol. 2008;26:5261–5268
  33. Danila DC, Rathkopf DE, Morris MJ, et al. Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. J Clin Oncol. 2008;26:5019;[Abstract]
  34. Reid AH, Attard G, Danila DC, et al. A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts). J Clin Oncol. 2009;27:5047;[Abstract]

PII: S1078-1439(10)00003-7

doi: 10.1016/j.urolonc.2009.12.023

Urologic Oncology: Seminars and Original Investigations
Volume 29, Issue 6 , Pages 676-681 , November 2011

Article Tools

* Image Usage & Resolution